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1. Introduction 
Among neurodegenerative disease, dementia is the one which affected cerebral cortex. (Grabowski and 
Damasio, 2004). It has enormous price to community, i.e., higher cost to health and social services, directly and 
economic price regarding lost productivity of the carers, and families who give funding for the patients, 
indirectly. One of its type is Alzheimer’s disease (AD). First described by Alois Alzheimer in the early 20th 
century, he mentioned a middle-aged woman who had cognitive impairment, lower functional level, and 
experienced psychotic symptoms, i.e., auditory hallucinations, and delusions. (Lovestone, 2009). He also found 
neurofibrillary tangles and milar foci in his case. (Richards and Sweet, 2009).   
 Old-age people experience mild declining of memory, executive functioning, and agility to cognitive 
processing related to their aging process within normal limitation, however it is a different condition with the 
patients with dementia, they experience all of the symptoms, progressively.   (Solfrizzi et al., 2002). Nowadays, 
there is increasing prevalence of dementia. It is doubled from 5 to 8 percent at age 65 to 70, to 15 to 25 percent 
at age 75 to 80, and up to 40 to 50 percent over age 85. In 2050, there will be 11 to 16 million people with AD in 
United States of America, because of the increasing of aging population. (Richards and Sweet, 2009), and in 
United Kingdom there will be almost 1.8 million people with dementia by 2051.(Knapp et al., 2007). The 
clinical features of AD are: cognitive impairment, functional impairment, and neuropsychiatric manifestations, 
i.e., disturbing behaviour, changing mood, anxiety, changing personality, sleep disturbances, and psychosis. 
(Richards and Sweet, 2009; Lovestone, 2009). 
 
2. Definition 
Dementia is multiple cognitive deficits which develop in old age (usually above 65 years), manifested by 
impairment in the memory and at least impairment in one of the following area of cognitive, i.e., language, 
gnosis,praxis, and executive functioning, however, the consciousness is clear. (American Psychiatric 
Association, 2000; Richards and Sweet, 2009). 
 Among dementia the most frequent type is AD, it is defined by amyloid beta plaques, neurofibrillary 
tangles, and widespread loss of neurons, histologically. (Bennett, 2007; Lovestone, 2009; Fuller and Manford, 
2010; Augustine, 2012; Anonymous, 2013). 
 
3. Cognitive and Behavioural Features of Alzheimer’s Disease 
The gold standard for dementing illness when comparing it between each other is AD. The features of AD are 
well-characterized. (Levy and Chelune, 2007). The list below summarize the cognitive and behavioural features 
of AD: 
1. Cognitive Impairment 
Patients with dementia suffer from memory impairment, language impairment (aphasia), inability to do 
motor activities, although motor function is intact (apraxia), inability to recognize object, although the 
sensory function is intact (agnosia), and impairment in judgment, executive functioning, and visuospatial 
functioning. (Levy and Chelune, 2007; Lovestone, 2009; Richards and Sweet, 2009).  
2. Functional Impairment 
There must be a significant functional impairment compared with the previous level of functioning. 
(American Psychiatric Association, 2000). The deterioration of daily functioning of the AD patients have 
the most impact for them, and they need care for themself, as well as nursing- home residency, because of 
it. (Knapp et al., 2007; Lovestone, 2009; Alzheimer’s Association, 2012). There is also impairment in 
social functioning of dementia patients, resulting in withdrawal in social activities. (Richards and Sweet, 
2009). 
3. Neuropsychiatric Symptoms 
The most frequent of mood disturbance in AD patients is depression (Lovestone, 2009), occurring about 
half of patients with AD (Richards and Sweet, 2009), whilst mood elation, hypomania, and disinhibition 
are rare. (Lovestone, 2009; Richards and Sweet, 2009). The most common psychotic symptoms are: 
paranoid ideation, hallucination, and delusion. The personality is changed to somewhat their relatives 
describe as a ‘living bereavement’, and the patients might become fearful, anxious, flattening of affect, 
and experience apathy syndrome. (Lovestone, 2009; Richards and Sweet, 2009).   
4. Other Behavioural Symptoms 
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Patients with AD also experience altered circadian rhythm, incontinence, eating pattern, wandering, and 
aggression. (Lovestone, 2009; Richards and Sweet, 2009). 
 




Francis et al (1999), Sarter and Parikh (2005) have reviewed, at first, the studies of atropine and scopolamine 
which showed they impaired cognitive abilities in animals and humans, thus cholinergic system had an important 
role in cognitive functions. In another review by Tampi et al (2011), the cholinergic systems have experienced 
pathological state which cause Behavioural and Psychological Symptoms of Dementia (BPSD) over denervation 
of temporal and frontal cortices, and as Minger et al (2000), cited by Garcia-Alloza et al (2005) have written, 
BPSD may be linked with the absence of choline. Garcia-Alloza et al (2005) have also found, aggressive 
behaviour have been related to low levels of cholineacetyltransferase (ChAT) and acetylcholinesterase (AChE). 
Almost a decade ago, there was a consensus that cholinergic augmentation was effective in developing memory, 
concentration, attention, and psychiatric symptoms of AD, discreetly. (Grabowski and Damasio, 2004). Until 
now, many drug studies have been done in relation with the cholinergic neurons in AD. 
 
 
  Figure 1. Major acetylcholine projections via brainstem. Major neurotransmitter projections, part 4: 
acetylcholine via brainstem. Acetylcholine projections originating in the brainstem extend to many brain regions, 
including the prefrontal cortex, basal forebrain, thalamus, hypothalamus, amygdala, and hippocampus. These 
projections may regulate arousal, cognition, and other functions. PFC, prefrontal cortex; BF, basal forebrain; S, 
striatum; NA, nucleus accumbens; T, thalamus; HY, hypothalamus; A, amygdala; H, hippocampus; NT, 
brainstem neurotransmitter centers; SC, spinal cord; C, cerebellum. Adapted from: Stahl, S.M. (2008). Stahl’s 
Essential Psychopharmacology Neuroscientific Basis and Clinical Applications. 3rd ed. New York: Cambridge 
University Press. 
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Figure 2. Major acetylcholine projections via basal forebrain. Major neurotransmitter projections, part 
5: acetylcholine via basal forebrain. Cholinergic neurons originating in the basal forebrain project to the 
prefrontal cortex, hippocampus, and amygdala; they are believed to be involved in memory. PFC, prefrontal 
cortex; BF, basal forebrain; S, striatum; NA, nucleus accumbens; T, thalamus; HY, hypothalamus; A, amygdala; 
H, hippocampus; NT, brainstem neurotransmitter centers; SC, spinal cord; C, cerebellum. Adapted from: Stahl, 
S.M. (2008). Stahl’s Essential Psychopharmacology Neuroscientific Basis and Clinical Applications. 3rd ed. 
New York: Cambridge University Press. 
4.1.2 Serotonin 
Tampi et al (2011) have reviewed, auditory and visual hallucinations were associated with serotonin receptor 
polymorphism, and the presence of visual hallucination was associated with Ser23 allele. It was concluded that 
psychosis and behaviour phenotype were associated with the serotonin transporter promoter region (5-HTTPR) I 
allele. In another study by Garcia-Alloza (2005), they found that overactivity was associated with 5-
hydroxytryptamine (5-HT) levels in Brodmann area 10 (frontal cortex), and psychosis was associated with 5-HT 
levels in Brodmann area 20 (temporal cortex). They also found women with AD experienced delusions higher 
than men, in relation with the ratio of 5-HT/ AChE in temporal cortex.  
4.1.3 Dopamine 
It has been thought that symptoms of aggression and psychosis in white subjects with AD have been  related 
with dopamine receptor genes DRD1 B2/ B2 homozygotes, and the carriers have been more likely to experience 
hallucination and be aggressive. Psychosis has been related with the DRD3 1/ 1 or 2/ 2 homozygotes, and DRD3 
polymorphism. Delusions have been experienced by the carriers of DRD3 1 allele. (Sweet et al., 1998; Holmes 
et al., 2001).    
 
4.2 Amyloid β Protein (Aβ Protein) 
Recently, it is known that the cognitive disturbance in patients with AD is because of widespread synapses loss 
in cortical regions. The cause of synaptotoxicity in AD is the self-aggregation of Aβ into soluble low-n 
oligomers. Animal and postmortem studies have complemented in vitro studies that has shown on synapses the 
deleterious effect of Aβ oligomers. In human studies, soluble Aβ associated with synapse loss and cognitive 
impairment, in the early event of AD. (Richards and Sweet, 2009). Another evidence shows that mutations in 
amyloid precursor protein (APP), resulting from unindirectional cascade, has risen to neurofibrillary tangle and 
plaque formation, whilst in tauopathies, although mutation in tau gene has risen tangle formation, there is not 
plaque formation. (Lovestone, 2009). 
 
4.3 Apolipoprotein ε (APOE) 
Apolipoprotein ε4 allele gene (APOE4) is related with the late-onset AD. The risk of people who carry APOE4 
in familial or sporadic cases are higher than people who do not carry it. Two- to fourfold increased risk have 
been found for people who have a copy of APOE4, and four- to eightfold increased risk for people who have two 
copies of it. (Richards and Sweet, 2009). Tampi et al (2011) have reviewed that in patients with AD: 1) The 3/ 4 
genotype of APOE4 caused higher rates of psychosis and depression when compared to control, 2) Significantly 
lower epsilon 2 allele of APOE in the depressive group when compared to control and it caused symptoms of 
depression in late-onset AD.      
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5. The Interplay of Cognitive and Behavioural Features of Alzheimer’s Disease, Environmental and 
Social Factors, and Their Relative Influences to Patients Quality of Life 
Kasl-Godley and Gatz (2000) have reviewed, the demented people have well defined cognitive and functional 
impairments, however, their subjective experience of these impairments  are the area which need further 
investigations. It might be undetected, underutilized, and coping and adaptation are unfacilitated because of the 
limited information. For example, symptom of depression, which is frequent among patients with AD, it reflects 
sadness because of inability to function dependently, and loss of intellectual capabilities, together with 
attenuation of control and mastery. The cognitive and behaviour symptoms of patients with dementia are not 
only an expression of the elemental disease mechanism, however they also show the environmental and social 
context, as well as patient’s reactions and perception. Spector et al (2000), have reviewed it is important for the 
patient with AD to get better understanding of his/ her environment, which will improve his/ her self-esteem and 
sense of control. An appropriate design of the structure and lightning of their environment can improve activities 
of daily living, e.g., taking shower, wearing clothes, and consuming food. 
 Alzheimer’s Disease could have effects for the patients, e.g., inability to get around home and 
functioning which lead to confusion, losing independence, and reduce self-esteem because of physical and 
mental changes which lead to social isolation, difficulties in planning activities and completing tasks which lead 
to relatives help and increased anxiety about future. (WebMD, 2013). Therefore, it is an important thing to 
educate the patients, the patients’s family and their caregivers. For the patients, education is needed to give 
information about, e.g.,  improving their compliance to medications, the benefit of doing exercise, healthy diet, 
and cognitive stimulation. For the family members, education is to give advices about, e.g., safety concerns 
associated with falls, driving, fire arms, living alone, and social engagement. As for the caregivers, they should 
be educated about, e.g., sleep hygiene and daily schedule, strategies to prevent stress and lassitude, future need 
for long-term care placement, and dealing and treating with behavioural and psychological issues. (Manepalli et 
al., 2009).   
 Samus et al (2005) have reviewed, quality of life has a subjective component in its traditional 
definition, which is, the individual has the chance to rate her or his own quality of life. In  patients with 
dementia, some of them are incompetent in reflecting their internal states. Thus, it is important to find and 
develop which quality of life rating scale that suits for every patient. Gonzalez-Salvador et al (2000) have 
studied, worse orientation, depressive symptoms, increased functional dependence, and anxiolytics treatment 
were associated with low quality of life. In one study, Samus et al (2005) have concluded, the care environment 
did not have an impact in quality of life, however, symptoms of aggression and agitation were correlated with it. 
In the future, studies in relation with quality of life of patients with AD should have been done to gain further 
knowledge about it. 
 
6. Conclusion 
People will have a greater risk to develop AD as they grow older, and it is a debilitating disease for them, as it 
continues to progress to the further stage. Their condition is getting worse when it has reached the last stage of 
the disease. The clinical features of AD are: cognitive impairment, functional impairment, and neuropsychiatric 
symptoms. All of these features have been thought to be related with the neurotransmitters, Aβ Protein, and 
APOE. They are disturbing for the patients, their family, and the caregivers which can change their lifestyle. A 
full understanding of the disease could reduce the stress between the patients, their family, and the caregivers.   
 The cognitive and behavioural features of AD are related with the patient’s quality of life. Therefore, 
these features have to be managed and treated properly. The lifestyle management and psychosocial intervention 
can improve quality of life of patients with AD. It requires strong effort and motivation from patients, their 
family members, and caregivers to gain an exceptional quality of life for the patients with AD. Designing the 
appropriate treatment for each patient with AD is important to develop their quality of life. Hence, more studies 
are needed to conclude which treatment and management might increase the quality of life of patients with AD.  
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